Beta-blockers linked to reduced mortality in HFrEF, A-fib
Julia Cadrin-Tourigny, M.D., from the Université de Montréal, and colleagues examined the impact of ?-blockers on mortality and hospitalizations in patients with AF and HFrEF in the AF-CHF trial. Among 1,376 subjects randomized in the trial, the authors propensity-matched those without ?-blockers at baseline to a maximum of two exposed patients.